Revisiting the role of measurable residual disease in FLT3 mutated acute myelogenous leukemia

Expert Rev Hematol. 2024 Apr 23. doi: 10.1080/17474086.2024.2347303. Online ahead of print.NO ABSTRACTPMID:38654593 | DOI:10.1080/17474086.2024.2347303

Source: Expert Review of Hematology - April 24, 2024 Category: Hematology Authors: H åkon Reikvam Richard Dillon Source Type: research